← Back to Search

Uricosuric Agent

AR882 Dose 2 for Gout

Phase 2
Waitlist Available
Research Sponsored by Arthrosi Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 14 weeks
Awards & highlights

Study Summary

This trial will test a new drug, AR882, to see if it can lower uric acid levels in gout patients safely.

Eligible Conditions
  • Gout
  • High Uric Acid

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~14 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 14 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Serum urate (uric acid) (sUA) level < 6 mg/dL following 6 weeks of dosing
Secondary outcome measures
Area under the plasma concentration-time curve (AUC)
Incidence of Adverse Events
Maximum Observed Plasma Concentration (Cmax)
+2 more

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Group 2Experimental Treatment2 Interventions
AR882 Dose 1 x 2 weeks, then Dose 2 x 10 weeks
Group II: Group 1Experimental Treatment1 Intervention
AR882 Dose 1 x 12 weeks
Group III: Group 3Placebo Group1 Intervention
AR882 matching placebo x 12 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AR882 Dose 1
2021
Completed Phase 2
~140
AR882 Dose 2
2021
Completed Phase 2
~140

Find a Location

Who is running the clinical trial?

Arthrosi TherapeuticsLead Sponsor
6 Previous Clinical Trials
218 Total Patients Enrolled
2 Trials studying Gout
72 Patients Enrolled for Gout
R Keenan, MDStudy ChairArthrosi Therapeutics
1 Previous Clinical Trials
42 Total Patients Enrolled
1 Trials studying Gout
42 Patients Enrolled for Gout

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Utah
How old are they?
18 - 65
What site did they apply to?
Arthrosi Investigative Site
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients
2021. "Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05119686.
~41 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top